Evaxion A/S (NASDAQ:EVAX) & Starpharma (OTCMKTS:SPHRY) Financial Review

Evaxion A/S (NASDAQ:EVAX) and Starpharma (OTCMKTS:SPHRY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Evaxion A/S and Starpharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-34.23%
Starpharma	N/A	N/A	N/A

Valuation & Earnings

This table compares Evaxion A/S and Starpharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53 million	3.32	-$7.71 million	($1.21)	-2.48
Starpharma	$8.18 million	30.91	-$5.07 million	N/A	N/A

Starpharma has higher revenue and earnings than Evaxion A/S.

Analyst Ratings

This is a summary of current recommendations for Evaxion A/S and Starpharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1	0	5	0	2.67
Starpharma	0	0	0	0	0.00

Evaxion A/S currently has a consensus target price of $11.00, indicating a potential upside of 266.67%. Given Evaxion A/S’s stronger consensus rating and higher possible upside, analysts plainly believe Evaxion A/S is more favorable than Starpharma.

Institutional & Insider Ownership

11.0% of Evaxion A/S shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Evaxion A/S has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Starpharma has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.

Summary

Starpharma beats Evaxion A/S on 6 of the 11 factors compared between the two stocks.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

About Starpharma

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.